Signet Therapeutics (Shenzhen) Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Shenzhen Guangdong China

Primary Industry

Biotechnology

About

Established in 2020 and based in Shenzhen, China, Signet Therapeutics (Shenzhen) Co., Ltd. is a healthcare technology company that provides cancer innovative prescription drugs. The company is mainly involved in the field of chemical pharmacy, targeted drugs, medical, and health. The founder and CEO Dr. Haisheng Zhang graduated from Harvard University and worked at the Dana-Farber cancer institute. It has new drug research and development center in Shenzhen and Boston, and closed a round of pre-series A funding in August 2023. In December 2024, the firm raised over CNY 70 million in pre-series A funding. The company's main business is research and development of immune cell technology, biomedical technology, and cancer innovative prescription drugs. The company has a self-developed disease model platform that uses in the field of stomach cancer, bowel cancer, lung cancer, and breast cancer. The company’s revenue is generated by providing targeted cancer drugs. The company will use the pre-series A funding to support the Phase I clinical trial of the first pipeline product, SIGX1094, and to accelerate the IND filing process for the second pipeline product.

Current Investors

Tiantu Capital, Leaguer Group, Sky 9 Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.